GLOBAL IMMUNOGLOBULIN MARKET 2022-2028

 

TABLE OF CONTENTS

1.     GLOBAL IMMUNOGLOBULIN MARKET – SUMMARY

2.     INDUSTRY OUTLOOK

2.1. IMPACT OF COVID-19 ON THE IMMUNOGLOBULIN MARKET

2.2. KEY INSIGHTS

2.2.1.    DEVELOPMENT OF NEW PURIFICATION METHODS

2.2.2.    INCREASING PREFERENCE FOR PERSONALIZED MEDICINES

2.3. PORTER’S FIVE FORCES ANALYSIS

2.3.1.    THREAT OF NEW ENTRANTS

2.3.2.    THREAT OF SUBSTITUTES

2.3.3.    BARGAINING POWER OF BUYERS

2.3.4.    BARGAINING POWER OF SUPPLIERS

2.3.5.    THREAT OF COMPETITIVE RIVALRY

2.4. MARKET ATTRACTIVENESS INDEX

2.5. VENDOR SCORECARD

2.6. KEY MARKET STRATEGIES

2.6.1.    PRODUCT LAUNCHES & DEVELOPMENTS

2.6.2.    PARTNERSHIPS & AGREEMENTS

2.7. MARKET DRIVERS

2.7.1.    GROWTH IN THE GERIATRIC POPULATION

2.7.2.    PREVALENCE OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS

2.7.3.    INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES

2.8. MARKET CHALLENGES

2.8.1.    HIGH COST OF THERAPY

2.8.2.    HIGH RISK OF SIDE EFFECTS DUE TO THE USE OF IMMUNOGLOBULIN

2.9. MARKET OPPORTUNITIES

2.9.1.    INCREASING ADOPTION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) TREATMENTS

2.9.2.    GROWING CLINICAL TRIALS

3.     GLOBAL IMMUNOGLOBULIN MARKET OUTLOOK – BY TYPE

3.1. IGG

3.2. IGA

3.3. IGM

3.4. IGE

3.5. IGD

4.     GLOBAL IMMUNOGLOBULIN MARKET OUTLOOK – BY DELIVERY MODE

4.1. INTRAVENOUS

4.2. SUBCUTANEOUS

4.3. INTRAMUSCULAR

5.     GLOBAL IMMUNOGLOBULIN MARKET OUTLOOK – BY APPLICATION

5.1. HYPOGAMMA GLOBULINEMIA

5.2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

5.3. PRIMARY IMMUNODEFICIENCY DISEASES

5.4. MYASTHENIA GRAVIS

5.5. MULTIFOCAL MOTOR NEUROPATHY

5.6. IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

5.7. INFLAMMATORY MYOPATHIES

5.8. SPECIFIC ANTIBODY DEFICIENCY

5.9. GUILLAIN-BARRE SYNDROME

5.10.               OTHER APPLICATIONS

6.     GLOBAL IMMUNOGLOBULIN MARKET OUTLOOK – BY END-USER

6.1. HOSPITALS & CLINICS

6.2. HOMECARE

7.     GLOBAL IMMUNOGLOBULIN MARKET OUTLOOK – BY SALES CHANNEL

7.1. HOSPITAL PHARMACY

7.2. SPECIALTY PHARMACY

7.3. OTHER SALES CHANNELS

8.     GLOBAL IMMUNOGLOBULIN MARKET – REGIONAL OUTLOOK

8.1. NORTH AMERICA

8.1.1.    MARKET BY TYPE

8.1.2.    MARKET BY DELIVERY MODE

8.1.3.    MARKET BY APPLICATION

8.1.4.    MARKET BY END-USER

8.1.5.    MARKET BY SALES CHANNEL

8.1.6.    COUNTRY ANALYSIS

8.1.6.1.        UNITED STATES

8.1.6.2.        CANADA

8.2. EUROPE

8.2.1.    MARKET BY TYPE

8.2.2.    MARKET BY DELIVERY MODE

8.2.3.    MARKET BY APPLICATION

8.2.4.    MARKET BY END-USER

8.2.5.    MARKET BY SALES CHANNEL

8.2.6.    COUNTRY ANALYSIS

8.2.6.1.        UNITED KINGDOM

8.2.6.2.        GERMANY

8.2.6.3.        FRANCE

8.2.6.4.        SPAIN

8.2.6.5.        ITALY

8.2.6.6.        REST OF EUROPE

8.3. ASIA-PACIFIC

8.3.1.    MARKET BY TYPE

8.3.2.    MARKET BY DELIVERY MODE

8.3.3.    MARKET BY APPLICATION

8.3.4.    MARKET BY END-USER

8.3.5.    MARKET BY SALES CHANNEL

8.3.6.    COUNTRY ANALYSIS

8.3.6.1.        CHINA

8.3.6.2.        JAPAN

8.3.6.3.        INDIA

8.3.6.4.        SOUTH KOREA

8.3.6.5.        ASEAN COUNTRIES

8.3.6.6.        AUSTRALIA & NEW ZEALAND

8.3.6.7.        REST OF ASIA-PACIFIC

8.4. LATIN AMERICA

8.4.1.    MARKET BY TYPE

8.4.2.    MARKET BY DELIVERY MODE

8.4.3.    MARKET BY APPLICATION

8.4.4.    MARKET BY END-USER

8.4.5.    MARKET BY SALES CHANNEL

8.4.6.    COUNTRY ANALYSIS

8.4.6.1.        BRAZIL

8.4.6.2.        MEXICO

8.4.6.3.        REST OF LATIN AMERICA

8.5. MIDDLE EAST AND AFRICA

8.5.1.    MARKET BY TYPE

8.5.2.    MARKET BY DELIVERY MODE

8.5.3.    MARKET BY APPLICATION

8.5.4.    MARKET BY END-USER

8.5.5.    MARKET BY SALES CHANNEL

8.5.6.    COUNTRY ANALYSIS

8.5.6.1.        UNITED ARAB EMIRATES

8.5.6.2.        SAUDI ARABIA

8.5.6.3.        TURKEY

8.5.6.4.        SOUTH AFRICA

8.5.6.5.        REST OF MIDDLE EAST & AFRICA

9.     COMPETITIVE LANDSCAPE

9.1. BIOTEST AG

9.2. CHINA BIOLOGIC PRODUCTS INC

9.3. GRIFOLS SA

9.4. LFB GROUP

9.5. CSL BEHRING

9.6. KEDRION BIOPHARMA

9.7. OCTAPHARMA AG

9.8. TAKEDA PHARMACEUTICAL COMPANY LIMITED

9.9. BIO PRODUCTS LABORATORY

9.10.               SHANGHAI RAAS BLOOD PRODUCTS CO LTD

9.11.               PFIZER INC

9.12.               SANQUIN PLASMA PRODUCTS BV

9.13.               ADMA BIOLOGICS

9.14.               SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD

9.15.               KAMADA LTD

10. RESEARCH METHODOLOGY & SCOPE

10.1.               RESEARCH SCOPE & DELIVERABLES

10.2.               SOURCES OF DATA

10.3.               RESEARCH METHODOLOGY

 

TABLE LIST

TABLE 1: GLOBAL IMMUNOGLOBULIN MARKET, BY REGIONAL OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 2: VENDOR SCORECARD

TABLE 3: GLOBAL IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)

TABLE 4: GLOBAL IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)

TABLE 5: GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)

TABLE 6: GLOBAL IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)

TABLE 7: GLOBAL IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)

TABLE 8: GLOBAL IMMUNOGLOBULIN MARKET, BY REGIONAL OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 9:   NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 10: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)

TABLE 11: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)

TABLE 12: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)

TABLE 13: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)

TABLE 14: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)

TABLE 15: EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 16: EUROPE IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)

TABLE 17: EUROPE IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)

TABLE 18: EUROPE IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)

TABLE 19: EUROPE IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)

TABLE 20: EUROPE IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)

TABLE 21: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 22: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)

TABLE 23: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)

TABLE 24: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)

TABLE 25: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)

TABLE 26: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)

TABLE 27: LATIN AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 28: LATIN AMERICA IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)

TABLE 29: LATIN AMERICA IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)

TABLE 30: LATIN AMERICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)

TABLE 31: LATIN AMERICA IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)

TABLE 32: LATIN AMERICA IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)

TABLE 33: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 34: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)

TABLE 35: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)

TABLE 36: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)

TABLE 37: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)

TABLE 38: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)

 

FIGURE LIST

FIGURE 1: MARKET ATTRACTIVENESS INDEX

FIGURE 2: GLOBAL IMMUNOGLOBULIN MARKET, BY TYPE, 2021 & 2028 (IN %)

FIGURE 3: GLOBAL IMMUNOGLOBULIN MARKET, BY IGG, 2022-2028 (IN $ MILLION)

FIGURE 4: GLOBAL IMMUNOGLOBULIN MARKET, BY IGA, 2022-2028 (IN $ MILLION)

FIGURE 5: GLOBAL IMMUNOGLOBULIN MARKET, BY IGM, 2022-2028 (IN $ MILLION)

FIGURE 6: GLOBAL IMMUNOGLOBULIN MARKET, BY IGE, 2022-2028 (IN $ MILLION)

FIGURE 7: GLOBAL IMMUNOGLOBULIN MARKET, BY IGD, 2022-2028 (IN $ MILLION)

FIGURE 8: GLOBAL IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2021 & 2028 (IN %)

FIGURE 9: GLOBAL IMMUNOGLOBULIN MARKET, BY INTRAVENOUS, 2022-2028 (IN $ MILLION)

FIGURE 10: GLOBAL IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS, 2022-2028 (IN $ MILLION)

FIGURE 11: GLOBAL IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR, 2022-2028 (IN $ MILLION)

FIGURE 12: GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, 2021 & 2028 (IN %)

FIGURE 13: GLOBAL IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2028 (IN $ MILLION)

FIGURE 14: GLOBAL IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, 2022-2028 (IN $ MILLION)

FIGURE 15: GLOBAL IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2028 (IN $ MILLION)

FIGURE 16: GLOBAL IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2028 (IN $ MILLION)

FIGURE 17: GLOBAL IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2028 (IN $ MILLION)

FIGURE 18: GLOBAL IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2028 (IN $ MILLION)

FIGURE 19: GLOBAL IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2028 (IN $ MILLION)

FIGURE 20: GLOBAL IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2028 (IN $ MILLION)

FIGURE 21: GLOBAL IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2028 (IN $ MILLION)

FIGURE 22: GLOBAL IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2028 (IN $ MILLION)

FIGURE 23: GLOBAL IMMUNOGLOBULIN MARKET, BY END-USER, 2021 & 2028 (IN %)

FIGURE 24: GLOBAL IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2028 (IN $ MILLION)

FIGURE 25: GLOBAL IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2028 (IN $ MILLION)

FIGURE 26: GLOBAL IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2021 & 2028 (IN %)

FIGURE 27: GLOBAL IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2028 (IN $ MILLION)

FIGURE 28: GLOBAL IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2028 (IN $ MILLION)

FIGURE 29: GLOBAL IMMUNOGLOBULIN MARKET, BY OTHER SALES CHANNELS, 2022-2028 (IN $ MILLION)

FIGURE 30: GLOBAL IMMUNOGLOBULIN MARKET, REGIONAL OUTLOOK, 2021 & 2028 (IN %)

FIGURE 31: UNITED STATES IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 32: CANADA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 33: UNITED KINGDOM IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 34: GERMANY IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 35: FRANCE IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 36: SPAIN IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 37: ITALY IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 38: REST OF EUROPE IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 39: CHINA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 40: JAPAN IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 41: INDIA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 42: SOUTH KOREA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 43: ASEAN COUNTRIES IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 44: AUSTRALIA & NEW ZEALAND IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 45: REST OF ASIA-PACIFIC IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 46: BRAZIL IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 47: MEXICO IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 48: REST OF LATIN AMERICA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 49: UNITED ARAB EMIRATES IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 50: SAUDI ARABIA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 51: TURKEY IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 52: SOUTH AFRICA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 53: REST OF MIDDLE EAST & AFRICA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

 

The prevalence of autoimmune disorders and immunodeficiency diseases drive the global immunoglobulin market.

 

MARKET OUTLOOK

A study by Triton Market Research suggests that the global immunoglobulin market would exhibit an uptrend trend at a CAGR of 6.77% over the forecast period of 2022-2028.

The market’s growth is supported by driving forces like the increase in the global geriatric population, increasing incidence of age-related diseases, the prevalence of autoimmune disorders, increase in research & development activities and prevalence of immunodeficiency diseases. In contrast, the high price associated with immunoglobulin therapy and the high risk of side effects due to its use are the factors that can challenge the market’s growth.

On the other hand, the increasing adoption of intravenous immunoglobulin (IVIG) treatments and the rising number of clinical trials being conducted indicate an overall positive outlook for the immunoglobulin market.

 

Get more insights into the Global Immunoglobulin Market:

 

https://www.tritonmarketresearch.com/reports/immunoglobulin-market

 

REGIONAL OUTLOOK

The immunoglobulin market covers North America, the Asia-Pacific, Europe, Latin America, the Middle East, and Africa. 

North America is the global leader in the immunoglobulin market and is expected to continue its dominance until the end of the forecast period. The region is home to top companies like Pfizer Inc, CSL Behring, ADMA Biologics, and others, which supports the market’s growth.

In addition, due to the increased incidence of various diseases in the United States and Canada, the immunoglobulin market presents an opportunity for increased use of immunoglobulin. Further, it is anticipated that an increase in product approvals by the US Food and Drug Administration will increase the demand for and adoption of immunoglobulin products in the region.

 

COMPETITIVE OUTLOOK

The key players listed in the global immunoglobulin market include Pfizer Inc, Bio Products Laboratory, Grifols SA, Octapharma AG, China Biologic Products Inc, ADMA Biologics, Sichuan Yuanda Shuyang Pharmaceutical Co Ltd, CSL Behring, Kedrion Biopharma, Kamada Ltd, LFB Group, Sanquin Plasma Products BV, Shanghai RAAS Blood Products Co Ltd, Takeda Pharmaceutical Company Limited, and Biotest AG.

Biotest AG is a globally renowned company that supplies plasma protein products and biotherapeutic medications. Its products are primarily utilized in hematology, clinical immunology, and acute care medicine. The company’s value chain ranges from pre-clinical & clinical development to marketing and distribution. Biotest AG produces albumins, clotting factors, and immunoglobulins obtained from human blood plasma. The business was established in 1946 and currently markets its product in more than 90 nations around the globe. Biotest AG sells its goods directly through its own subsidiaries or with regional distributors and marketing partners.

 

 

SEGMENTATION

1.     BIOTEST AG

2.     CHINA BIOLOGIC PRODUCTS INC

3.     GRIFOLS SA

4.     LFB GROUP

5.     CSL BEHRING

6.     KEDRION BIOPHARMA

7.     OCTAPHARMA AG

8.     TAKEDA PHARMACEUTICAL COMPANY LIMITED

9.     BIO PRODUCTS LABORATORY

10. SHANGHAI RAAS BLOOD PRODUCTS CO LTD

11. PFIZER INC

12. SANQUIN PLASMA PRODUCTS BV

13. ADMA BIOLOGICS

14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD

15. KAMADA LTD